A lateral flow immunoassay for the rapid, simultaneous qualitative direct detection and differentiation of nucleocapsid antigen from SARS-CoV-2, as well as influenza type A and type B, directly from anterior nasal or nasopharyngeal swab specimens. The test is authorized for use on specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five days of onset of symptoms.